FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067592430> ?p ?o ?g. }

• W2067592430 endingPage "528" @default.
• W2067592430 startingPage "525" @default.
• W2067592430 abstract "Asthma is characterized by chronic airway inflammation, reversible airway obstruction and airway hyperresponsiveness [1]. Although airway inflammation along with eosinophil accumulation and activation can be associated with airway obstruction and hyperresponsiveness, some studies in asthmatics and animal asthma models have suggested contradicting roles of eosinophils in asthma pathogenesis [2-9]. In this issue of the journal, Ishiura and colleagues evaluate the associations between airway eosinophil accumulation induced by repeated intranasal polymyxin-B treatment in guinea pigs and bronchial responsiveness to methacholine, acetylcholine and histamine challenges. Interestingly, they found that airway eosinophilia coexisted with actual reduction in airway responsiveness to all three challenges [10]. Thus, the question that has been brought to the forefront is the role(s) of eosinophils in the pathogenesis of asthma. Airway eosinophilic inflammation has been recognized for nearly 100 years in asthmatic lung tissue [11]. Typically, the airway wall of fatal asthmatics is thickened and the airway lumen is occluded by mucus plugs with large numbers of eosinophils [12, 13](Fig. 1a). These pathologic findings may well explain the severe airflow obstruction in fatal asthma attacks. Increased numbers of activated eosinophils have also been extensively reported in various airway samples from living asthmatics with different severity of the disease. These samples include bronchial biopsy tissue, alveolar tissue, bronchoalveolar lavage (BAL) and induced sputum [14-18]. Since eosinophils are known to produce, store and release many proinflammatory cytokines and mediators, they are considered to play a critical role in the pathophysiology of asthma. For example, mediators from eosinophils such as major basic protein, eosinophil cationic protein (ECP) and cysteinyl leukotrienes (CLTs) have been demonstrated to contribute to bronchoconstriction and airway hyperresponsiveness [19-22]. In fact, allergen challenge in atopic asthma has been shown to induce a significant eosinophil infiltrate into the airways in the late asthmatic reaction (Fig. 1b), which is accompanied by increased levels of ECP and leukotriene C4 (LTC4) in BAL, and a significant drop in forced expiratory volume in 1 s (FEV1) [23]. Strong correlations between baseline airway eosinophils and airway hyperresponsiveness as well as FEV1 have also been reported in patients with asthma, especially mild asthma [4-6, 24]. In animal models of asthma, eosinophils were also shown to be associated with increased airway responsiveness to methacholine challenge [9]. IL-5 is one of the key cytokines in the recruitment, activation and survival of eosinophils. IL-5 knockout mice and anti-IL-5 antibody-treated mice demonstrated significantly lower numbers of lung eosinophils and reduced airway responsiveness to methacholine challenge [25-27]. These animal studies suggest that IL-5 elimination from airways could attenuate eosinophilic inflammation with consequent improvement in pulmonary function. (a) Fatal asthmatic bronchial tissue demonstrating a large amount of eosinophil accumulation with a marked bronchial epithelial desquamation. (H–E staining, original mag. × 400.) (b) Allergen challenge in atopic asthma causing significant eosinophil influx into the bronchoalveolar lavage. (Diff-Quick staining, original mag. × 1000.) Although eosinophils are likely to play important roles in asthma, some studies suggest that asthma and/or airway hyperresponsiveness/obstruction could exist without significant eosinophil accumulation in the airway [8, 28-31]. Fatal asthma can be presented as a ‘sudden-onset’ or ‘slow-onset’ process. In contrast to slow-onset asthma, sudden-onset fatal asthma is characterized by large numbers of neutrophil accumulating in the airway mucosa with minimal numbers of eosinophils [32]. Additionally, studies in severe living asthmatics suggested that a subgroup of patients demonstrated no obvious eosinophil infiltration in the large airway mucosa. Neutrophils were the predominant cells in this subgroup of asthmatics, which showed a lower FEV1 than those severe asthmatics with airway eosinophils [28, 29]. A recent study also indicated that clinically unstable severe corticosteroid-dependent asthmatics had decreased numbers of eosinophils in the airway mucosa compared with mild asthmatics [33]. These results suggest that eosinophils may not be essential in certain populations of severe asthmatics. It is important to note that some studies in mild and moderate asthmatics failed to establish a significant inverse relationship between pulmonary function and eosinophil numbers or ECP levels in bronchial biopsy tissue and BAL samples [2, 3]. Moreover, a recent clinical study using a single dose of humanized anti-IL-5 antibody treatment in mild asthmatics did not show an improvement in the early or late asthmatic reaction following an allergen challenge, although reduction of eosinophil levels was found in both peripheral blood and induced sputum [34]. Furthermore, another recent study even demonstrated that airway hyperresponsiveness could not be observed in the late asthmatic reaction, although there was an airway eosinophilic inflammation [35]. These human studies suggest that eosinophils may not necessarily be involved in the pathophysiology of a subgroup of asthmatics with different severity of the disease. Some animal studies also suggest that airway eosinophilia may not be important in the development of allergen-induced airway hyperresponsiveness. For example, Tournoy et al. [8] demonstrated that airway hyperresponsiveness could occur with or without airway eosinophil influx and elevated serum allergen-specific IgE in a murine asthma model induced by house dust mite allergen. Additionally, IL-5-deficient mice could present a similar airway hyperresponsiveness compared with the wild-type mice after nasal inoculation with nematode Nippostrongylus brasiliensis[30]. In this issue of the journal [10], results from Ishiura et al. further support the concept that eosinophils may not be required for the development of airway hyperresponsiveness. The specific point from this study is that airway eosinophilia may be associated with reduced airway responsiveness to methacholine, acetylcholine and histamine challenges in polymyxin-B-treated guinea pigs. It is interesting to note that another study demonstrating the lack of airway eosinophil accumulation to increase airway hyperresponsiveness was also conducted in guinea pigs [36]. It is not clear if the genetic background of guinea pigs could contribute to this specific phenomenon. It is important to determine if this observation could be duplicated in mouse asthma models in future studies. As for the potential mechanisms of eosinophils in the reduction of airway hyperresponsiveness, study from Ishiura and colleagues suggests that cyclooxygenase pathway products of arachidonic acids, such as prostaglandins E2 (PGE2) and I2 (PGI2), could play a role. Eosinophils are one of the major cellular sources for 5-lipoxygenase products of arachidonic acids such as CLTs. It has been shown that levels of CLTs were increased in asthmatic airways after allergen challenge [37]. In contrast to PGE2 and PGI2[38, 39], CLTs are able to cause significant bronchoconstriction and airway hyperresponsiveness [22]. Therefore, it is very intriguing why 5-lipoxygenase products from eosinophils seem to be suppressed in Ishiura's guinea pig model. How can the pros and cons story of eosinophils be reconciled? We suggest the following two points to reconcile the contradictory stories of eosinophils in asthma. First, asthma should be considered as a syndrome rather than a single disease. In this context, there may be several or many subgroups/phenotypes of asthma with different aetiologies or triggers. Some populations of asthmatics may be eosinophil-associated and some may not. Second, asthma pathogenesis is very complex and still uncertain. Current studies suggest that both chronic airway inflammatory and remodelling processes are involved [1]. Eosinophil accumulation may be only part of the processes which produce chronic changes in the airway. Eosinophil accumulation may also only exist intermittently as a result of different endogenous and exogenous stimulants. In the absence of airway eosinophils, the other inflammatory components (e.g. neutrophils and mast cells) and airway remodelling may be sufficient to contribute to the disease process [1, 40]. When eosinophils appear in the airway, they may or may not exacerbate asthma. In conclusion, the significance of eosinophils in asthma may be much more complicated than we thought several decades ago. We may need to realise that there is a heterogeneity issue for asthma and certainly for eosinophils (both the amount and activity) in asthmatic airways. Different types of airway inflammation such as eosinophilic and non-eosinophilic inflammation may characterize different phenotypes of asthma. In the future, these concepts need to be considered in research designs and in the selection of asthma therapy." @default.
• W2067592430 created "2016-06-24" @default.
• W2067592430 creator A5001290696 @default.
• W2067592430 creator A5033749081 @default.
• W2067592430 date "2001-04-01" @default.
• W2067592430 modified "2023-10-18" @default.
• W2067592430 title "Are eosinophils still important in asthma?" @default.
• W2067592430 cites W1874256351 @default.
• W2067592430 cites W1945512486 @default.
• W2067592430 cites W1963678276 @default.
• W2067592430 cites W1977093939 @default.
• W2067592430 cites W1987861537 @default.
• W2067592430 cites W1988145495 @default.
• W2067592430 cites W1988227673 @default.
• W2067592430 cites W1993997407 @default.
• W2067592430 cites W2003251689 @default.
• W2067592430 cites W2019282811 @default.
• W2067592430 cites W2019443108 @default.
• W2067592430 cites W2041771870 @default.
• W2067592430 cites W2047202466 @default.
• W2067592430 cites W2049472311 @default.
• W2067592430 cites W2051948045 @default.
• W2067592430 cites W2052260815 @default.
• W2067592430 cites W2061751962 @default.
• W2067592430 cites W2062179074 @default.
• W2067592430 cites W2072974313 @default.
• W2067592430 cites W2073989221 @default.
• W2067592430 cites W2079666008 @default.
• W2067592430 cites W2081323519 @default.
• W2067592430 cites W2083087446 @default.
• W2067592430 cites W2087911213 @default.
• W2067592430 cites W2090375776 @default.
• W2067592430 cites W2091981809 @default.
• W2067592430 cites W2095205058 @default.
• W2067592430 cites W2099159352 @default.
• W2067592430 cites W2106682746 @default.
• W2067592430 cites W2114518763 @default.
• W2067592430 cites W2116177799 @default.
• W2067592430 cites W2123069309 @default.
• W2067592430 cites W2130217674 @default.
• W2067592430 cites W2150547642 @default.
• W2067592430 cites W2154945180 @default.
• W2067592430 cites W2312870247 @default.
• W2067592430 cites W4231989633 @default.
• W2067592430 doi "https://doi.org/10.1046/j.1365-2222.2001.01095.x" @default.
• W2067592430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11359418" @default.
• W2067592430 hasPublicationYear "2001" @default.
• W2067592430 type Work @default.
• W2067592430 sameAs 2067592430 @default.
• W2067592430 citedByCount "11" @default.
• W2067592430 countsByYear W20675924302012 @default.
• W2067592430 countsByYear W20675924302014 @default.
• W2067592430 countsByYear W20675924302015 @default.
• W2067592430 countsByYear W20675924302018 @default.
• W2067592430 crossrefType "journal-article" @default.
• W2067592430 hasAuthorship W2067592430A5001290696 @default.
• W2067592430 hasAuthorship W2067592430A5033749081 @default.
• W2067592430 hasConcept C203014093 @default.
• W2067592430 hasConcept C2776042228 @default.
• W2067592430 hasConcept C2777037409 @default.
• W2067592430 hasConcept C71924100 @default.
• W2067592430 hasConceptScore W2067592430C203014093 @default.
• W2067592430 hasConceptScore W2067592430C2776042228 @default.
• W2067592430 hasConceptScore W2067592430C2777037409 @default.
• W2067592430 hasConceptScore W2067592430C71924100 @default.
• W2067592430 hasIssue "4" @default.
• W2067592430 hasLocation W20675924301 @default.
• W2067592430 hasLocation W20675924302 @default.
• W2067592430 hasOpenAccess W2067592430 @default.
• W2067592430 hasPrimaryLocation W20675924301 @default.
• W2067592430 hasRelatedWork W1506200166 @default.
• W2067592430 hasRelatedWork W1995515455 @default.
• W2067592430 hasRelatedWork W2047305992 @default.
• W2067592430 hasRelatedWork W2048182022 @default.
• W2067592430 hasRelatedWork W2080531066 @default.
• W2067592430 hasRelatedWork W2748952813 @default.
• W2067592430 hasRelatedWork W2899084033 @default.
• W2067592430 hasRelatedWork W3031052312 @default.
• W2067592430 hasRelatedWork W3032375762 @default.
• W2067592430 hasRelatedWork W3108674512 @default.
• W2067592430 hasVolume "31" @default.
• W2067592430 isParatext "false" @default.
• W2067592430 isRetracted "false" @default.
• W2067592430 magId "2067592430" @default.
• W2067592430 workType "article" @default.